Skip to main content

Volume 15 Supplement 10

Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors—proceedings from breast cancer expert group meeting


Publication of this supplement has been supported by sponsorship. AstraZeneca International has supported in meeting arrangement and sponsored the development of article. The article has undergone the journal's standard peer review process for supplements. The Supplement Editor declares that they have no competing interests.

Munich, Germany21 October 2018

  1. The therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer ta...

    Authors: Shaheenah Dawood, Maria Konstantionva, Rebecca Dent, Florencia Perazzo, Sung-Bae Kim, Cynthia Villarreal-Garza, Sandra Franco, Ming-Shen Dai and Sergio Simon
    Citation: BMC Proceedings 2021 15(Suppl 10):15

Annual Journal Metrics

  • 2022 Citation Impact
    0.914 - SNIP (Source Normalized Impact per Paper)
    0.506 - SJR (SCImago Journal Rank)

    2023 Usage 
    196 Altmetric mentions